TABLE 1

Drug susceptibility patterns of 171 clinical M. tuberculosis isolates

Susceptibility or resistance category or drug(s)Total patients (n = 171)New patients (n = 97)Previously treated patients (n = 74)
No.% (95% CI)No.% (95% CI)No.% (95% CI)
Overall susceptibility to first-line drugs10159.1 (52.0–66.4)7880.4 (72.5–88.3)2331.1 (20.5–41.6)
Overall first-line drug resistance7040.9 (33.6–48.3)1919.6 (11.7–27.5)5168.9 (58.4–79.5)
INH6135.7 (28.5–42.9)1313.4 (6.6–20.2)4864.9 (54.0–75.7)
RIF4626.9 (20.3–33.6)77.2 (2.1–12.4)3952.7 (41.3–64.1)
SM3520.5 (14.4–26.5)1313.4 (6.6–20.2)2229.7 (19.3–40.1)
EMB179.9 (5.5–14.4)22.1a1520.3 (11.1–29.4)
PZA2615.2 (9.8–20.6)33.1a2331.1 (20.5–41.6)
Overall MDR4325.2 (18.6–31.7)66.2 (1.4–11.0)3750.0 (38.6–61.4)
INH + RIF105.9 (2.3–9.4)11.0a912.1 (4.7–19.6)
INH + RIF + SM74.1 (1.1–7.1)22.1a56.8a
INH + RIF + EMB10.6a0011.4a
INH + RIF + PZA74.1 (1.1–7.1)0079.5 (2.8–16.1)
INH + RIF + SM + EMB31.8a0034.1a
INH + RIF + SM + PZA42.3a11.0a34.1a
INH + RIF + EMB + PZA42.3a0042.3a
INH + RIF + SM + EMB + PZA74.1 (1.1–7.1)22.1a55.4a
Susceptibility to all second-line drugs15288.9 (84.2–93.6)9598.0a5777.0 (67.4–86.6)
Overall second-line drug resistance1911.1 (6.4–15.8)22.1a1722.9 (13.4–32.6)
CAP42.3a0045.4a
KAN31.8a0034.1a
AKM21.2a0022.7a
OFX1810.5 (5.9–15.1)22.1a1621.6 (12.2–31.0)
Overall pre-XDR158.7 (4.5–13.0)11.0a1414.9 (6.8–23.0)
CAP42.3a0041.4a
KAN31.8a0031.4a
AKM21.2a0020
OFX148.2 (4.1–12.3)11.0a1313.5 (5.7–21.3)
Overall XDR31.8a0034.1a
CAP + OFX10.6a0011.4a
CAP + KAN + AKM + OFX21.2a0022.7a
  • a 95% CI was not determined.